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1. Introduction 
Glycosylation is the most common and the most diverse form of co- and post-translational 
modifications. An analysis of the Swiss-PROT database has led to the estimation that more 
than 50% of all proteins are glycosylated. Genes coding proteins involved in all types of 
oligosaccharides biosynthesis represent 0.5 to 1% of the translated genome (Dennis et al., 
1999). Glycoproteins are found ubiquitously in an organism either as soluble (intracellular 
or extracellular) or as membrane bound molecules. There is a great structural variety of 
glycoproteins based on the type, length and linkage of a carbohydrate components as well 
as the degree of saturation of potential glycosylation sites on the protein itself.  
Carbohydrates can have a significant influence on the physicochemical properties of 
glycoproteins, affecting their folding, solubility, aggregation and degradation. Furthermore, 
glycan chains in glycoproteins play key roles in many biological processes such as 
embryonic development, immune response and cell-cell interactions in which sugar-sugar 
or sugar –protein specific recognition is involved (Wei & Li , 2009).  
Altered glycosylation is an universal feature of cancer cells, and certain glycan structures 
and glycoproteins are well-known tumor markers. These include for example glycoproteins 
such as carcinoembryonic antigen (CEA), commonly used as a marker of colorectal cancer, 
prostate-specific antigen (PSA) and CA-125 used in the diagnosis of ovarian cancer (Drake et 
al.,  2010). High expression of some glycosyl epitopes for example sialyl Lewis a, sialyl 
Lewis x, Lewis y, promotes invasion and metastasis. Antibodies against Lewis antigens are 
used for evaluation of specimens from breast, bladder, colorectal, esophageal and lung 
carcinomas (Drake et al., 2010). Glycans can regulate different aspects of tumor progression, 
including proliferation, invasion and metastasis. Cancer-related changes in glycosylation 
can reflect disease specific alterations in glycan biosynthetic pathways. These include 
variations in the expression and activity of glycosyltransferases, enzymes that add 
monosaccharides to acceptors, i.e. proteins or growing carbohydrate chains and 
glycosidases which catalyze the hydrolysis of the glycosidic linkage to release sugars.  
There are three most common categories of protein glycosylation 1) N-glycosylation, where 
glycans are attached to asparagine residues in a consensus sequence N-X-S/T via  
N-acetylglucosamine (GlcNAc) residue; 2) O-glycosylation, where glycans are attached to 
serine or threonine via N-acetylgalactosamine (GalNAc) residue (mucin type glycosylation); 
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3) O-GlcNAcylation, where single N-acetylglucosamine residues are attached by O-linkage 
to serine and threonine residues (Fig.1). N-oligosaccharides have a common core structure of 
five sugars and differ in their outer branches. They are divided into three main classes: high 
mannose, complex and hybrid. High mannose oligosaccharides have additional mannoses 
linked to the pentasaccharide core and forming the branches. Complex-type 
oligosaccharides contain characteristic GlcNAc and Gal residues and are often terminated 
with sialic acid residues. Complex type oligosaccharides can be bi-, tri- or tetraantennary.  
 
Fig. 1. Examples of carbohydrate structures. Arrows indicate the residues attached by 
glycosyltransferases  the expression of which was studied in thyroid tumors:  
GnT-V - N-acetylglucosaminyltransferase V , FUT8 –  1,6 –fucosyltransferase,  
OGT – O-GlcNAc transferase 
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Hybrid oligosaccharides contain one branch that has a complex structure and one or more 
high-mannose branches (Stanley et al., 2009). The mucin-type O-glycan, with N-
acetylgalactosamine (GalNAc) at the reducing end, is a very common form of O-
glycosylation in humans (Brockhausen, 1999; Wopereis et al., 2006). In O-glycosylated 
proteins, oligosaccharides range in size from 1 to >20 sugars, displaying considerable 
structural diversity. In total, 8 mucin-type core structures can be distinguished, depending 
on the second sugar and its sugar linkage, of which cores 1–6 and core 8 have been described 
in humans. The N-acetylgalactosamine may be extended with sugars such as galactose, N-
acetylglucosamine, fucose or sialic acid but not mannose, glucose or xylose residues 
(Brockhausen et al., 2009). The structural variability of glycans is dictated by tissue-specific 
regulation of glycosyltransferase genes, acceptor and sugar nucleotide donors availability 
and by competition between enzymes for acceptor intermediates during glycan elongation. 
Glycosyltransferases catalyze the transfer of a monosaccharide from specific sugar 
nucleotide donors onto particular position of a monosaccharide in a growing glycan chain in 
one or two possible anomeric linkages (either  or ) (Dennis et al., 1999). O-GlcNAcylation 
is a specific type of glycosylation since O-GlcNAc residues are not elongated and do not 
form complex structure. This dynamic and inducible modification is more similar to 
phosphorylation than to classical glycosylation (Hart & Akimoto, 2009).  
2. Glycosylation in thyroid cancer 
It is known that glycosylation profiles change significantly during oncogenesis (Wei & Li, 
2009). Detection of tumor specific alterations could be potentially useful for cancer 
diagnostics. Lectins are a very good tool for the detection of changes in glycosylation. They 
are a group of proteins or glycoproteins that have affinity to carbohydrates and can 
reversibly and specifically interact with certain glycan structural motifs. Some lectins are 
widely used in cancer diagnostics. For example Helix pomatia agglutinin (HPA) which 
detects GalNAc1-4 Gal, is a part of a panel of markers for histological characterization of 
gastric cancer specimens. HPA as well as Ulex europaeus agglutinin (UEA)(recognize Fuc1-
2Gal) is also used in breast cancer biopsy assessment (Drake et al., 2010).  
It has been suggested that lectins might be useful histochemical tools for detecting and 
analyzing poly-N-acetyllactosamines in thyroid normal and malignant tissues (Ito N et al., 
1995,1996). Staining with lectins in combination with endo-beta-galactosidase digestion 
demonstrated that poly-N-acetyllactosaminyl structures ubiquitously and consistently 
produced in thyroid papillary carcinomas are highly heterogeneous in their chain length 
and branching status and quite different from those produced in other thyroid neoplasms 
(Ito N et al., 1995, 1996). Studies concerning glycosylation of intracellular proteins in benign 
and malignant thyroid neoplasms showed significant quantitative and qualitative 
differences in binding of Erythrina cristagalli (ECA) and Ricinus communis (RCA-120) 
agglutinins that recognize N-acetyllactosamine or galactose residues (Krześlak et al., 2003). 
In the majority of carcinoma samples lectin binding to cytosolic proteins was definitely 
weaker in comparison with adenomas and non-neoplastic specimens which suggests 
alterations in glycosylation of proteins in thyroid malignant tumors. Also binding  patterns 
of Sambucus nigra (SNA) and Maakia amurensis (MAA) agglutinins which recognized sialic 
acids are different in malignant tumors compared with benign thyroid lesions (Krześlak et 
al., 2007). 
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Changes in glycosylation are not the random consequence of disordered biology in tumor 
cells. It is characteristic that of all the possible glycan biosynthetic changes, only a limited 
subset of changes are correlated with malignant transformation (Varki et al., 2009).  
2.1 N-acetylglucosaminyltransferase V  
The most widely occurring glycosylation change in cancers is enhanced 1,6 GlcNAc side 
chain branching (see Fig.1.). Increased amounts of 1,6 GlcNAc branched carbohydrates 
have been linked to tumor invasion and metastasis in case of several human cancers 
including breast and colon. This carbohydrate structure is a product of increased activity of 
N-acetylglucosaminyltransferase V (GnT-V) (Fernandes et al., 1991; Seelentag et al., 1998; 
Granovsky et al., 2000).  
Ito Y et al. (2006) have studied by immunohistochemistry the expression of GnT-V in 
thyroid normal and cancer tissues. They found expression of this enzyme in 66 of 68 cases of 
papillary carcinomas, 10 of 23 - follicular carcinomas, 9 of 13 - follicular adenomas and 6 of 
28 - anaplastic carcinomas but the enzyme was not expressed in normal thyroid tissue. It has 
been shown that matriptase, a tumor-associated type II transmembrane serine protease is a 
target protein for GnT-V and 1,6 GlcNAc branching of oligosaccharide on matriptase 
increases resistance of this protein to proteolytic degradation. Increased expression of 
matriptase and GnT-V levels were characteristic for papillary carcinoma. Although 
matriptase is proposed to modulate the metastatic potential of some cancer cells, it is not 
likely that the matriptase and GnT-V promote invasion and metastasis of papillary thyroid 
cancers. The levels of  expression of both matriptase and GnT-V were significantly high in 
microcarcinomas. In case of poorly differentaiated and undifferentiated (anaplastic) 
carcinomas which show local and distant metastasis, expression of these proteins 
significantly decreased. Thus matriptase and GnT-V probably play a role in early phases of 
papillary carcinomas growth, but not in their progression (Miyoshi et al., 2010). 
2.2 Changes in sialic acid expression  
Residues of sialic acid are usually found at the non-reducing terminal position of 
glycoconjugate sugar chains, 2,3- or 2,6-linked to a galactose (Gal), or 2,6-linked to a  
N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc) residues (Harduin-
Lepers et al., 2001). Changes in sialic acid expression may be important in cancer 
progression and metastasis for several reasons. First, sialic acid can prevent cell-cell 
interactions through charge repulsion effects; second, sialylated structures can be 
recognized by cell adhesion molecules belonging to selectin or siglec families; third, the 
addition of sialic acid may mask the underlying sugar structure, thus avoiding recognition 
by other lectins such as galectins (Dall’Olio & Chiricolo, 2001).  
Nozawa et al. (1999) investigated immunohistochemically the reactivity of monoclonal 
antibody of FB21, which recognizes a sialic acid-dependent carbohydrate epitope with 
thyroid lesions in order to evaluated the potential diagnostic usefulness of sialic acid 
expression analysis. The increased FB21 antigen reactivity appeared to be characteristic for 
follicular and papillary thyroid tumors but not for medullary thyroid carcinoma. FB21 
reacted with almost all cases of follicular carcinomas and less than half of cases of papillary 
carcinomas. A positive reaction was found on the cell surface membranes or apical parts of 
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neoplastic follicles. The normal thyroid follicles, goiters, medullary and anaplastic 
carcinomas were negative for FB21 reactivity. High frequency of reactivity of follicular 
carcinoma with FB21 suggested that it may be useful in diagnosis of this histological type of 
thyroid tumors.  
Differences in sialic acid level on luminal surface between thyroid carcinomas and normal 
thyroid tissue or adenomas and goiters was observed in histochemistry studies using sialic 
acid binding lectins Tritrichomonas mobilensis lectin (TML), Maackia amurensis agglutinin 
(MAA) and Sambucus nigra agglutinin (SNA) (Babál et al., 2006). Malignant tumors 
especially papillary carcinoma had an increased level of sialic acid mainly alpha-2,3-linked 
and recognized by MAA. These results suggest that increased membrane sialic acid on 
thyroid gland cells may be an important diagnostic indicator, that could be useful in the 
distinction of malignant from benign thyroid lesions (Babál et al., 2006).  
Cellular sialic acid level is mainly controlled metabolically by sialyltransferases and 
sialidases. Human sialyltransferases are a  family of at least 18 different members that 
catalyse the transfer of sialic acid residues from their activated form CMP-sialic acid to 
terminal position of oligosaccharide chains (Harduin-Lepers et al., 2001). Changes in 
sialyltransferases expression have been observed in cancer tissues and the regulation of their 
expression is achieved mainly at the transcriptional level (Dall’Olio & Chiricolo, 2001). 
Sialidases catalyse the removal of sialic acid residues which is an initial step in the 
degradation of glycoproteins. There are only few studies focusing on sialic acid metabolism 
in thyroid tissue. Thyroid sialyltransferase 1 (-galactoside -2,6-sialyltransferase) and 4 (-
galactoside -2,3-sialyltransferase) mRNA level and activity are increased in Graves disease 
(Kiljański et al., 2005). Sialyltransferase 1 showed also a very evident increase of expression 
in  autonomously functioning thyroid nodules (AFTNs) versus their surrounding tissues 
(Eszlinger et al., 2004). Since sialyl Lewis  epitopes are more frequently expressed in 
papillary carcinomas than Lewis a and Lewis b it is speculated that a specific 
glycosyltransferase, i.e. 2,3 sialyltransferase may be highly activated as compared with 
1,4 fucosyltransferase. Moreover, this sialyltransferase seems to be more strongly enhanced 
in papillary carcinoma than in follicular carcinoma (Kamoshida et al., 2000). 
2.3 Fucosylation  
Fucosylated glycans are synthesized by fucosyltransferases. Thirteen fucosyltransferase 
genes have thus far been identified in the human genome. Based on the site of fucose 
addition  fucosyltransferases are classified into 1,2 (FUT1, FUT2), 1,3/4 (FUT 3, 4, 5, 6, 7, 
9), 1,6 (FUT8) and O-fucosyltransferase (POFUT1) groups (Becker & Lowe, 2003; Ma et al., 
2006). Two additional 1,3 fucosyltransferase genes, FUT10 and FUT11 and one  
O-fucosyltransferase gene have been identified in the human genome but their protein 
products have not yet been demonstrated to be enzymatically active although they share 
primary sequence similarity with active fucosyltransferases. Certain types of fucosylated 
glycoproteins for example alfa-fetoprotein and several kinds of antibodies, which recognize 
fucosylated oligosaccharides such as sialyl-Lewis a/x, have been used as tumor markers 
(Miyoshi et al., 2008). The Lewis blood group antigens are a related set of glycans that carry 
1,2/1,4 fucose residues (Fig.2). Although growing evidence supports the functional 
significance of fucosylation at various pathophysiological steps of carcinogenesis and tumor 
progression, the significance of this modification in thyroid cancer has not been widely 
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explored. The results of studies of Vierbuchen et al. (1992) concerning blood group antigens 
in medullary thyroid carcinoma (MTC) and normal thyroid tissue supported the general 
concept demonstrated in other carcinomas, that fucosyl- and sialyltransferases might be  
preferentially activated. The Lewis antigens were absent in normal tissue and present in 
MTC. Miettinen and Kärkkäinen (1996) analysed immunohistochemically a wide range of 
thyroid tumors and non-neoplastic tissues by using CD15 antibody, which recognized Lewis x 
blood group antigen. Nodular goiter and papillary hyperplasia cases either showed no 
reactivity or were focally positive. Most papillary carcinomas were CD15 positive usually in 
the majority of tumor cells. However only 50% of follicular carcinomas were positive and 
anaplastic carcinomas were negative. Similar results were obtained by Fonseca et al. (1996, 
1997) who found by using SH1 antibodies that most of papillary and follicular carcinomas 
were extensively immunoreactive for Lewis x antigen in contrast to the absence of 
expression of this antigen in normal thyroid. 
 
Fig. 2. Lewis antigens.  
Ito Y et al. (2003) performed immunohistochemical studies of FUT8 expression in thyroid 
cancers. FUT8 catalyses the transfer of a fucose residue to the C6 position of the innermost 
GlcNAc residue of N-linked oligosaccharides on glycoproteins to produce core fucosylation 
(Fig.1.). The expression of FUT8 was very low in normal follicules. A high expression of 
FUT8 was observed in 33.3% of papillary carcinomas and the incidence was directly linked 
to tumor size and lymph node metastasis. But the number of cases of follicular carcinomas 
with high expression of FUT8 was rather low. These results suggest that FUT8 expression 
may be a key factor in the progression of thyroid papillary carcinomas, but not follicular 
carcinomas ( Ito Y et al., 2003; Miyoshi et al., 2010). 
2.4 O-GlcNAcylation 
O-GlcNAcylation is a post-translational protein modification consisting of  
N-acetylglucosamine moiety attached by O-glycosidic linkage to serine and threonine 
residues (Hart et al., 2007). O-GlcNAc is a unique type of glycosylation since it is not 
elongated to more complex glycan structures and is nearly exclusively on cytoplasmic and 
nuclear proteins. Furthermore, the addition and removal of O-GlcNAc moieties cycles in a 
very dynamic and inducible manner in response to different stimuli such as hormones, 
growth factors, and mitogens. That makes O-GlcNAcylation more similar to 
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phosphorylation than to classical glycosylation. O-GlcNAcylation is one of the most 
common post-translational modifications. So far, nearly one thousand of cellular proteins 
have been identified to be O-GlcNAcylated (Butkinaree et al., 2010). These proteins belong 
to diverse functional groups and include nuclear pore proteins, transcription factors, RNA 
binding proteins, cytoskeletal proteins, chaperones, phosphatases, kinases and other 
enzymes (Zachara & Hart, 2006). There is growing evidence that O-GlcNAc modification is 
involved in a wide range of biological processes, such as signal transduction, transcription, 
cell cycle progression and metabolism (Hart et al., 2007). O-GlcNAc can modulate protein 
function by regulating protein activity, protein-protein interaction, localization and protein 
degradation (Zeidan & Hart, 2010). 
There is a relationship between O-GlcNAcylation and phosphorylation. All O-GlcNAc 
modified proteins are also phosphoproteins and sometimes O-GlcNAc and O-phosphate 
moieties can compete for a binding site or alternatively O-GlcNAcylation and 
phosphorylation can compete via steric hindrance when the substrate modification sites are 
within several aminoacids from each other (Hu et al., 2010). However, unlike 
phosphorylation, where many kinases and phosphatases regulate the addition and removal 
of phosphate, O-GlcNAcylation is regulated only by two enzymes. The addition of  
O-GlcNAc to proteins is catalyzed by O-GlcNAc transferase (OGT) and its removal is 
catalyzed by O-GlcNAc- selective N-acetyl--D-glucosaminidase (O-GlcNAcase, OGA) (Iyer 
& Hart, 2003). OGT is encoded by a single gene on X chromosome (Lubas & Hanover, 2000; 
Shafi et al., 2000). Although there is only one OGT gene, human OGT has at least three 
different isoforms because of alternative splicing (Love et al., 2003, Hanover et al., 2003). The 
main difference between isoforms is the number of tetratricopeptide repeats in N-terminal 
region. The OGT isoforms differ also in their tissue distribution and probably they may have 
different functions (Lazarus et al., 2006).  
The cloned sequence of O-GlcNAcase was found to be identical to that of MGEA5 
(meningioma-expressed antigen 5), which was identified genetically in human meningiomas 
(Heckel et al., 1998; Comtesse et al., 2001). MGEA5 localizes to chromosome 10q24.1-q24.3 
region. O-GlcNAcase seems to be a bifunctional enzyme. The N-terminus contains  
O-GlcNAc hydrolase activity and C-terminus bears a putative histone acetyltransferase 
(HAT) domain (Toleman et. al, 2004). O-GlcNAcase is reported both HAT and O-GlcNAcase 
activity in vitro. 
There is growing evidence that perturbation in O-GlcNAc signaling is involved in the 
pathology of cancers. Overexpression of OGT causes defective cytokinesis increasing 
polyploidy of cells, a feature common to many cancer cells (Slawson et al., 2005). O-GlcNAc 
is present on many transcription and cell cycle regulatory proteins. The protooncogene  
c-Myc which regulates transcription of genes involved in cell proliferation, apoptosis and 
metabolism is modified by O-GlcNAc at Thr58 and this potentially stabilizes the protein 
(Kamemura et al., 2002). The important tumor suppressor p53, which is mutant or 
dysregulated in many cancers bears O-GlcNAc at Ser149. Increased O-GlcNAcylation of p53 
at Ser149 results in decreased p53 ubiquitination and stabilizes the p53 protein (Yang WH et 
al., 2006).  
Several malignancies have been shown to have increased level of O-GlcNAcylation 
compared to normal tissue (Gu Y et al., 2010; Mi et al., 2011; Caldwell et al., 2010). Elevated 
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OGT mRNA expression was found in breast cancer cell lines and breast invasive ductal 
carcinoma compared with normal breast cells and normal breast tissue (Caldwell et. al., 
2010; Krześlak et al., 2011a). It has been shown that poorly differentiated breast tumors 
(grade II and III) had significantly higher OGT expression than grade I tumors and lymph 
node metastasis is significantly associated with decreased MGEA5 mRNA expression 
(Krześlak et al., 2011a). The intracellular O-GlcNAcylation has been found to be also 
associated with the pathogenesis of chronic lymphatic leukemia –CLL (Shi et al., 2010).  
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Fig. 3. OGT and MGEA5 expression in thyroid lesions. The expression of OGT and MGEA5 
was studied by real time RT-PCR method in series of 25 samples of non-neoplastic lesions -
NN (nodular goiters), 8 samples of follicular adenoma - ADE, 25 samples of papillary 
carcinoma – PTC (12 cases of non-metastatic –N and 13 cases of cancers with lymph node 
metastasis- M), 4 samples of follicular carcinomas - FTC and 1 sample of anaplastic cancer. 
TaqMan Gene Expression assays including fluorogenic, FAM labeled probes and sequence 
specific primers for MGEA5, OGT and GAPDH were purchased from Applied Biosystems. 
Assays numbers of OGT, MGEA5 and GAPDH were Hs00201970, Hs00269228 and 
Hs99999905, respectively. Abundance of OGT and MGEA5 mRNA in samples were 
quantified by the ΔCt method. ΔCt (Ctgene – CtGAPDH) values were recalculated into 
relative copy number values (number of OGT or MGEA5 mRNA copies per 1000 copies of 
GAPDH mRNA). The groups were compared using Mann-Whitney rank sum test.  
P value < 0.05 was considered statistically significant (non published data). 
O-GlcNAcase activity was found to be increased in thyroid papillary, follicular and 
anplastic cancers in comparison with non-neoplastic lesions and benign tumors. O-GlcNAc-
modified proteins in thyroid cells had a predominantly nuclear distribution and were more 
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abundant in non-neoplastic lesions than in tumors (Krześlak et al., 2010). However, our 
preliminary studies concerning O-GlcNAc cycling enzymes expression did not show any 
significant differences in mRNA expression of MGEA5 between thyroid cancers and non-
neoplastic lesions (Fig.3). Contrary, OGT mRNA expression seems to be elevated in cancer 
samples in comparison to nodular goiters or benign tumors. Moreover, expression of OGT 
mRNA was higher in papillary carcinoma with lymph node metastasis compared to non-
metastatic carcinoma. High expression was also found in case of anaplastic carcinoma. 
These results might suggest that O-GlcNAc transferase is associated with thyroid cancer 
progression. 
Caldwell et al. (2010) have provided evidence that the reduction abnormally elevated OGT 
and O-GlcNAc levels in breast cancer cells inhibits cancer cell growth in vitro and in vivo and 
also diminishes breast cancer invasion. Decreasing O-GlcNAc levels through knockdown of 
OGT in cancer cells promotes elevation of the cell-cycle regulator p27kip1 and reduces 
expression of FoxM1 and its transcriptional target matrix metalloproteinase-2. Our studies 
concerning O-GlcNAc role in anaplastic thyroid cancer cells 8305C showed that down-
regulation of O-GlcNAcase enhanced both basal and IGF-1 stimulated Akt1 activation and 
cell proliferation (Krześlak et al., 2011b). In cells treated with O-GlcNAcase inhibitor –
PUGNAc or specific for O-GlcNAcase  siRNAs phosphorylation of kinase GSK3 and cyclin 
D1 level were higher than in control cells. These findings suggest that increased 
proliferation of  8305C cells with down-regulation of O-GlcNAcase at least partially depends 
on IGF-1 – Akt1 – GSK3 – cyclin D1 pathway.  
Although abnormal O-GlcNAcylation seems to be a feature of cancer cells its role in 
tumorigenesis and cancer progression has not been fully elucidated and further 
investigations in this area are needed. However, it seems that O-GlcNAc transferase 
expression might be a marker for some tumor progression including thyroid. Moreover, 
regulation of O-GlcNAc may be a promissory novel therapeutic strategy for cancer and OGT 
may be in future a potential drug target. 
3. Glycoproteins as thyroid cancer biomarkers 
Glycoproteins seem to provide an abounding source for discovering biomarkers for thyroid 
lesions. Gene expression profiling studies identified some genes coding glycoproteins for 
example MET, SERPINA1, TIMP1, FN1, CD44, SDC4, DPP4 and PROS1 as important 
thyroid cancer markers (Griffith et al., 2006). These significantly deregulated genes in 
thyroid cancer cells may help to develop a panel of markers with sufficient sensitivity and 
specificity for the diagnostic purpose. Studies of cell surface and secreted protein profiles of 
human thyroid cancer cell lines (FTC-133, TPC-1, XTC-1, ARO, DRO-1) revealed distinct 
glycoprotein patterns for each cell line (Arcinas et al., 2009). Of the 333 glycoproteins 
identified in the five thyroid cancer lines, nearly one third, 105, were found exclusively in a 
single cell line. FTC-133 and ARO had the fewest (7) and the most (34) uniquely identified 
glycoproteins, respectively. It is suggested that several glycoproteins have a potential as 
biomarkers for a specific type of thyroid cancer or as general thyroid cancer biomarkers. For 
example NCAM-1 is a glycoprotein biomarker candidate for differentiated cancers, 
syndecan-1 and cadherin-13 for follicular carcinoma, elastin microfibril interfacer-1, 
hyaluronan and proteoglycan link protein 1, ephrin-B-1 for anaplastic carcinoma, CD157 for 
Hürthle cell thyroid carcinoma (Arcinas et al., 2009).  
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Usefulness of some glycoprotein expression analysis for thyroid cancer diagnostics have 
been already extensively tested. 
3.1 Thyroglobulin 
Thyroglobulin (Tg) is a large glycoprotein produced by thyroid normal follicular cells and 
differentiated malignant cells. The production of Tg is low in poorly differentiated cells and 
absent in anaplastic thyroid cancer (Francis & Schlumberger, 2008). Thyroglobulin provides 
a matrix for the synthesis of the thyroid hormones, thyroxine (T4) and triiodothyronine (T3), 
and acts as a storage vehicle for iodine, in the form of iodinated tyrosyl residues (Vali et al., 
2000). Tg is a homodimer with molecular weight of 660 kDa and contains 10% of 
carbohydrate structures. Of the 20 putative N-linked glycosylation sites in the human 
thyroglobulin polypeptide chain, 16 were shown to be actually glycosylated in the mature 
protein (Yang SX et al., 1996). Eight of these confirmed glycosylation sites appear to be 
linked to complex-type oligosaccharide units containing fucose and galactose in addition to 
mannose and glucosamine. Five sites contain high mannose type units and two sites are 
linked to oligosaccharide units that may be either hybrid or complex structures (Yang SX et 
al., 1996). The oligosaccharides of Tg have been shown to affect the structure and function of 
Tg. They have an impact iodination and hormone synthesis, targeting of Tg to subcellular 
and extracellular compartments, interactions with a putative membrane receptor and 
immunoreactivity of Tg (Vali et al., 2000).  
Owing to thyroglobulin tissue specificity, its serum level is widely used as a marker for 
recurrence of thyroid carcinoma following total thyroidectomy. The improved sensitivity of  
thyroglobulin assays and the adoption of an international calibration standard have made 
thyroglobulin measurement an essential part of thyroid cancer monitoring (Lin, 2008; Ringel 
& Ladenson 2004). However, it ought to be remembered that there are some limitations of 
serum thyroglobulin measurement. The presence of anti-thyroglobulin antibodies interferes 
with measurements of Tg protein made either by immunometric assay or by 
radioimmunoassay (Feldt-Rasmussen & Rasmussen, 1985; Mariotti et al, 1995; Spencer, 
2004). Due to difficulties with antibody interference, there has been an interest in developing 
new techniques for thyroid carcinoma monitoring. One of these techniques is the detection 
of circulating thyroid cells by the measurement of thyroglobulin mRNA (Tg-mRNA) in 
peripheral blood (Ditkoff et al., 1996). However, there are contradicting results on the 
usefulness of Tg-mRNA detection in peripheral blood. Some authors suggested the 
usefulness of this method in the follow-up of thyroid cancer patients (Ringel et al., 1998, 
1999; Biscolla et al, 2000; Savagner et al., 2002) but others questioned its reliability (Bojunga 
et al., 2000; Eszlinger et al., 2002; Span et al., 2003, Elisei et al., 2004). Thyroglobulin mRNA 
may be expressed in very low concentrations by other cells in the body, including peripheral 
lymphocytes, through a process known as illegitimate transcription (Verburg et al., 2004).  
Since the serum Tg level is increased in the majority of patients with either benign or 
malignant thyroid nodules, its use is not recommended in the preoperative differentiation 
between thyroid lesions. However, it is suggested that the carbohydrate structure analysis of 
thyroglobulin might be useful for thyroid cancer diagnostics. During malignant 
transformation, epithelial cells modulate the glycosylation profile of their secretion proteins 
and these post-translational changes may represent specific markers which may be useful 
diagnostic or prognostic tools. The composition of carbohydrate chains on thyroglobulin 
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from thyroid carcinoma has been reported to differ from that in normal thyroid tissue 
(Maruyama et al., 1998; Shimizu et al., 2007a). Shimizu et al. (2007b) investigated Lens 
culinaris agglutinin (LCA)-reactive thyroglobulin ratio in serum to evaluate its usefulness for 
distinguishing between thyroid carcinoma and benign thyroid tumor. Their results were 
very promising. The Lens culinaris agglutinin-reactive thyroglobulin ratio was significantly 
lower in patients with thyroid carcinoma than in patients with benign thyroid tumor. 
Moreover, in cases of thyroid carcinoma with lymph node metastasis, Lens culinaris 
agglutinin-reactive Tg ratios were significantly decreased compared to patients with thyroid 
carcinoma without metastasis. Further studies confirm usefulness of the determination of 
LCA-reactive Tg ratios using an enzyme-linked immunosorbent assay for distinguishing 
between benign and malignant lesions (Kanai et al., 2009). 
3.2 Fibronectin 
Fibronectin (FN) is a high molecular mass adhesive glycoprotein present in the extracellular 
matrix that plays a significant role in cell adhesion, migration, growth, differentiation and 
the maintenance of normal cell morphology (Pankov & Yamada, 2002). Although fibronectin 
is encoded by a single gene it can exist in 20 different isoforms in humans as a results of 
alternative splicing and post-translational modifications. Fibronectin usually exists as a 
dimer composed of two ~250 kDa subunits linked by a pair of disulfide bonds near the C-
termini. Subunits are composed primarily of three types of repeating module (I, II and III). 
Sets of modules make up domains for binding to variety of extracellular and cell surface 
molecules including collagen, glycosaminoglycans, fibrin, integrins and FN itself 
(Wierzbicka-Patynowski & Schwarzbauer, 2003). FN isoforms can be divided in two groups: 
soluble plasma FNs which are synthesized predominantly in the liver by hepatocytes and 
the less-soluble cellular FNs synthesized by  other cell types. Heterogenity of fibronectin is 
also caused by post-translational modification. FN isoforms are glycoproteins that contain  
4-9% carbohydrate, depending on the cell type. Glycosylation sites reside predominantly 
within type III repeats and the collagen-binding domain. The physiological role of the 
carbohydrates is not certain, but they appear to stabilize FN against hydrolysis and 
modulate its affinity to some substrates (Pankov & Yamada, 2002). There are seven potential 
N-glycosylation sites in human FN, and these N-glycans are largely responsible for the 
carbohydrate content of this molecule. The N-glycan of plasma FN is composed of complex-
type biantennary oligosaccharides and is largely sialylated, whereas fibroblast-derived 
cellular FN contains fucose linked to the innermost N-acetylglucosamine (GlcNAc) and is 
less sialylated (Fukuda et al., 1982, Tajiri et al., 2005). Fetal and neoplastic cells 
predominantly express a uniquely glycosylated isoform called oncofetal fibronectin 
(OnfFN). This isoform is characterized by the presence of oncofetal domain situated in the 
COOH terminal region, which is absent in normal fibronectin. The oncofetal domain of FN 
is composed of an oligosaccharide linked to a hexapeptide by O-glycosylation (Matsuura et 
al., 1988).  
Fibronectin 1 was first reported to be overexpressed in papillary carcinomas (Huang et al., 
2001; Wasenius et al., 2003). Prasad et al. (2005) found that FN1 expression was significantly 
associated with malignancy and highly specific for carcinomas compared to adenomas and 
non-neoplastic tissues. Immunohistochemical analysis showed that FN1 was expressed in 61 
of 67 papillary carcinoma cases, 3 of 6 follicular carcinoma, 4 of 4 anaplastic carcinoma and  
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6 of 8 Hürthle cells carcinoma cases. Contrary expression of FN1 was observed only in 2 of 
29 samples of nodular goiters an 1 of 21 adenoma cases. Coexpression of FN1 with other 
markers such as galectin-3 or HBME1 was observed only in carcinomas (100% specific) 
while concurrent absence of FN1 and galectin-3 or HBME1 (Fn_Gal-3_ or FN_HBME1_ 
immunophenotype) was highly specific (96%) for adenomas (Prasad et al., 2005). Thus, this 
study suggest that fibronectin 1 is a very useful marker in the diagnosis of thyroid 
carcinomas. However, some other studies did not confirm high utility of fibronectin 1. 
Immunohistochemical studies of Nasr et al. (2006) showed that although FN1 was quite 
specific for papillary carcinomas, a large portion of PTC (31%) were negative. Even those 
cases that were positive showed weak and focal staining, and there was often significant 
background staining. The authors suggested  that low sensitivity, focal staining and high 
background positivity significantly impair the utility of  FN1 in diagnostics. 
Using the reverse transcription-PCR technique, Takano et al. (1998, 1999) have suggested 
that oncofetal fibronectin (onfFN) may be an accurate molecular preoperative  diagnostic 
marker for papillary thyroid carcinoma. They analyzed the expression of onfFN in fine-
needle  aspiration biopsies. The sensitivity and specificity of this method were 96% and 
100%, respectively. They also showed high onfFN expression in anaplastic cancer tissues 
and cell lines (Takano et al., 2007). It has been suggested that oncofetal fibronectin may be a 
better  tumor-specific marker in detecting minimal residual disease in differentiated thyroid 
carcinoma than thyroglobulin (Hesse et al., 2005). Thyroglobulin mRNA was thought to 
originate from circulating thyrocytes, but other studies demonstrated that physiological 
blood cells such as leukocytes are capable of ectopic Tg mRNA transcription (Verburg et al., 
2004) In order to monitor patients with DTC for minimal residual disease by blood assays, 
Hesse et al. (2005) developed and optimized a specific, sensitive real-time RT–PCR assay 
using FRET technology to quantify absolute amounts of onfFN templates. High expression 
rate of onfFN transcripts in DTCs was demonstrated, while onfFN mRNA was not found to 
be illegitimately transcribed by peripheral blood cells. The authors suggested that onfFN 
mRNA analysis may be a specific tool for monitoring micrometastases in the context of 
minimal residual disease or for assessing tumor response to therapy. Continuing their 
studies they performed the analysis of mRNA level in peripheral blood of PTC patients who 
were previously treated by thyreoidectomy and treated by levothyroxine to determine if 
onfFN levels are correlated with the status of the disease or with thyroid-stimulating 
hormone (TSH) serum concentrations (Wehmeier et al 2010). The mean value of onfFN 
mRNA in bloods from healthy subjects was used as control. OnfFN transcripts were highly 
abundant in the peripheral blood of the patients, but the levels of onfFN mRNA did not 
differ significantly among the patients who were free of the disease, had local residual 
disease or metastatic disease. However, there was a trend towards higher expression rates of 
onfFN mRNA in patients with metastases than those free of disease. Discrimination between 
the disease states was better without TSH stimulation. The authors suggest that circulating 
onfFN mRNA, may be a useful tool to detect circulating thyroid cancer cells. 
3.3 CD44 
The CD44 glycoprotein is an acidic molecule whose charge is largely determined by sialic 
acid. CD44 plays a critical role in a variety of cellular behaviors, including adhesion, 
migration, invasion, and survival. The main ligand for CD44 is a hyaluronan but CD44 has 
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an afifinity to other extracellular matrix constituents such as osteopontin, collagens, and 
matrix metalloproteinases (MMPs) (Cichy & Puré, 2003). The gene for CD44 contains 20 
exons, 12 of which are expressed by the most common form of CD44, referred to as standard 
CD44 (CD44s). Isoforms of CD44 are generated by the insertion of alternative exons (V1–
V11) at a single site within the membrane-proximal portion of the extracellular domain 
(Ponta et al., 2003). Molecules containing the variable exons or their peptide products are 
designated CD44v. The most abundant standard protein consists of three regions, a 72 
amino acid (aa) C-terminal cytoplasmic domain, a 21 aa transmembrane domain, and a 270 
aa extracellular domain (Goodison et al., 1999). The degree of glycosylation can affect the 
ligand binding characteristics of the protein and therefore alter its function. The regulation 
of the amount and the type of post-translational modification can add further diversity to 
the range of potential functions of CD44 isoforms. Expression of multiple CD44 isoforms is 
frequently upregulated during neoplastic transformation. CD44, particularly its variants, 
may be useful as a diagnostic or prognostic marker of malignancy (Goodison et al., 1999).  
Expression of CD44 both on mRNA and protein levels was intensively studied in thyroid 
pathological lesions in order to evaluate its utility in distinguishing benign and malignant 
tumors. Immunohistochemical and immunocytochemical analyses showed that CD44 
molecule was preferentially expressed in papillary thyroid carcinoma compared with other 
thyroid neoplasms and non-neoplastic lesions (Figge et al., 1994; Böhm et al., 2000; Kim et 
al., 2002). Variant isoforms of CD44 (CD44v3 and CD44v6) were detected in follicular and 
papillary carcinomas as well as in follicular adenomas but not in non-neoplastic lesions (Gu 
et al., 1998). The frequency of both variants expression was significantly higher in PTC with 
node metastasis than in PTC without metastasis (Gu et al., 1998). Since CD44v6 is not 
expressed by normal thyrocytes and is variably detected in benign and malignant lesions 
Gasbarri et al. (1999) suggested that it could be a preoperative marker to identify malignant 
lesions. Its immunodetection in cytologic specimens obtained by fine-needle aspiration 
biopsy could be useful for selecting those nodular lesions of the thyroid gland that need to 
be surgically resected (Gasbarri et al., 1999). Böhm et al. (2000) found that reduced level of 
CD44s in differentiated thyroid cancer patients seemed to be an independent prognostic 
factor for unfavorable disease outcome. Age older than 60 years, distant metastases and 
advanced pTNM stage were related to the loss of CD44s expression. 
The main problem in preoperative diagnostics of thyroid neoplastic lesions is distinguishing 
between follicular carcinomas and follicular adenomas. Nasir et al. (2004) tested usefulness 
of CD44v6 among other markers in differentiating benign and malignant follicular 
neoplasms. They found membranous CD44v6 staining in 81% of FTC but in only 20% of 
follicular adenomas and suggested that its immunohistochemical detection may be useful 
for follicular neoplasm diagnostics. Maruta et al. (2004) analysed CD44v6 immunostaining 
in fine-needle aspiration cytology of 35 follicular carcinoma specimens and 44 cases of 
follicular adenomas and observed positive reaction in 74% of carcinoma cases and 30% of 
adenomas. There was no correlation between the expression of CD44v6 in follicular 
carcinomas and characteristics such as capsular invasion, vascular invasion, metastasis, or 
tumor size (Maruta et al., 2004). 
Since CD44 is often detected in benign lesions its diagnostic importance is questioned by 
some authors (Nikiel et al., 2006). Matesa et al. (2007) analyzed CD44v6 mRNA expression 
in order to answer whether  the presence of macrophages and Hürthle cells are responsible 
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for positive expression detected in benign lesions. They found a statistically significant 
relationship between presence of Hürthle cells and positive expression of CD44v6 in 
nodular goiter cytological samples.  
3.4 Osteopontin 
Osteopontin (OPN) is an acidic hydrophilic glycophosphoprotein rich in aspartic acid, 
glutamic acid and serine and contains ~30 monosaccharides, including 10 residues of sialic 
acid. One carbohydrate chain is attached by N-glycosyl bond to protein and 5-6 chains are  
linked by O-glycosyl bond (Rangaswami et al., 2006). OPN is a member of a small integrin 
binding ligand N-linked glycoprotein (SIBLING) family of proteins which include bone 
sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialoprotein (DSPP), and matrix 
extracellular phoshoglycoprotein (MEPE) (Wai & Kuo, 2008). OPN functions by mediating 
cell-matrix interactions and cellular signaling through binding with integrin and CD44 
receptors. Many studies have indicated that OPN is highly expressed in several 
malignancies. OPN expression is associated with tumor invasion, progression or metastasis 
in breast, stomach, lung, prostate, liver and colon cancers (for a review see Wai & Kuo, 2008; 
Rangaswami et al., 2006). 
Castellone et al. (2004) showed that osteopontin was a major RET/PTC - induced 
transcriptional target in PC Cl3 thyroid follicular cells. RET/PTC also induced a strong 
overexpression of CD44 which is a cell surface signaling receptor for OPN. These results 
prompt further studies to ascertain whether OPN could be a useful PTC tumor marker. 
OPN expression was studied by immunohistochemistry in 117 samples of thyroid papillary 
cancer, benign lesions and normal tissues (Guarino et al., 2005). OPN was found to be 
overexpressed in PTCs compared with normal thyroid tissue, follicular adenomas and 
multinodular goiters. Moreover, OPN up-regulation was correlated with aggressive 
clinicopathological features of PTC. The prevalence and intensity of OPN staining were 
significantly correlated with the presence of lymph node metastases and tumor size. 
However, follicular variant of PTC had lower prevalance of OPN expression compared to 
classical type. Studies of Briese et al. (2010) on a large number of thyroid samples showed 
that normal thyroid was negative for OPN, thyroid adenomas were weakly OPN positive, 
whereas many carcinomas were strongly positive. However, there was no association 
between OPN expression and tumor size and metastasis status. 
mRNA level of SPP1 (osteopontin gene) was validated in a panel of 57 thyroid tumors 
using quantitative PCR (qPCR) (Oler et al., 2008). SPP1 was overexpressed in PTCs but the 
difference was not considered significant. However, SPP1 expression was associated with 
the presence of lymph node metastasis for tumors >1 cm. The expression levels of SPP1 in 
follicular variant of PTC and follicular carcinoma were lower than in classical type of 
PTC.  
Recently Wang et al. (2010) found that osteopontin expression is positively correlated in 
thyroid papillary carcinoma with phosphorylated c-Jun kinase (p-JNK). Activation of the 
JNK signaling pathway appears to be an important event in thyroid tumorigenesis and, 
perhaps, in tumor progression making p-JNK a possible target in cancer treatment. 
Coordinated expression of p-JNK and OPN immunoreaction suggest an involvement of 
both genes in the same molecular pathway in thyroid lesions (Wang et al., 2010). 
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3.5 NCAM 
Neuronal cell adhesion molecule (NCAM, CD56) mediates homotypic and heterotypic cell-
cell adhesion (Crossin & Krushel, 2000). NCAM structurally belongs to the immunoglobulin 
superfamily. The extracellular part of NCAM consists of five Ig-like domains and two 
fibronectin type III-like domains. Alternative mRNA splicing results in three major 
isoforms: a 120 kDa isoform which is predominantly expressed in normal and well 
differentiated tissues and a 140 and 180 kDa isoforms that are found predominantly in less 
differentiated or malignant cell types (Jensen & Berthold, 2007). NCAM is unique among 
adhesion molecules because it carries a large amount of the negatively charged sugar, 
polysialic acid (PSA) (Crossin & Krushel, 2000). The presence of PSA can affect the strength 
or stability of adhesion systems in which NCAM is involved.  
NCAM is present on follicular epithelial cells of the normal thyroid but its expression is 
reduced by malignant transformation and may affect the migratory capability of tumor cells 
(Zeromski et al., 1998, 1999; Satoh et al., 2001). Scarpino et al. (2007) analyzed NCAM 
expression in tissue sections of 61 cases of papillary thyroid carcinoma (PTC) using 
immunohistochemistry and quantitative real-time PCR. Reduced NCAM protein expression 
was observed by immunohistochemistry in all histological variants of PTC and also in 
lymph node metastases. Reduced expression of NCAM protein was associated with a 
significant reduction of NCAM mRNA in the tumor tissue compared with the paired 
normal thyroid tissue. Other studies showed NCAM to be extremely useful in the 
distinction between PTC and follicular benign or malignant lesions (El Demellawy et al., 
2008, 2009; Ozolins et al., 2010). El Demellawy et al. (2009) evaluated the diagnostic value of 
protein expression using antibodies against NCAM in normal follicular thyroid epithelium, 
benign thyroid lesions, and thyroid carcinomas. Their aim was to study the applicability of 
difference in NCAM expression as a marker that distinguishes PTC, including the follicular 
variant from other follicular thyroid lesions and follicular thyroid carcinoma. They found 
that NCAM is of value in distinguishing PTC from other thyroid follicular pathology with a 
sensitivity of 100% and a specificity of 100%. 
The potential role of NCAM in tumor cell biology was investigated by silencing the NCAM 
gene in the TPC1 thyroid papillary carcinoma cell line (Scarpino et al., 2007). The results 
confirm that modifications of NCAM expression cause profound alterations in the adhesive 
and migratory properties. However, contrary to the observation that loss of NCAM is 
usually associated with increased tumor invasiveness in vivo, NCAM-silenced TPC-1 cells 
were more adhesive to different extracellular matrix components, and were less efficient in 
cell migration and invasiveness. This discrepancy requires further investigations.  
3.6 TIMPs 
Tissue inhibitors of metalloproteinases (TIMPs) have a dual role in the process of tumor 
progression with both pro- and anti-tumorigenic activities. Although originally 
characterized by their ability to inhibit matrix metalloproteinases (MMPs) activity, TIMPs 
have additional biological activities and have been shown to regulate a number of cellular 
processes including cell growth, migration, and apoptosis (Stetler-Stevenson, 2008 ). Four 
TIMPs have been currently characterized in human and designated as TIMP-1, -2, -3 and -4. 
They are expressed by a variety of cell types and are present in most tissues and body fluids. 
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TIMP-1 gene differs from the other members of the family in having a short exon 1 that is 
transcribed but not translated. The function of exon 1 appears to be related to the control of 
the specificity of tissue expression and may contain tissue-specific repressor elements. 
TIMP-1 is a glycosylated protein  and the N-linked oligosaccharides are composed of sialic 
acid, mannose, galactose and N-acetylglucosamine. The TIMP-1 glycosylation seems to play 
a role in various functions including correct folding of the nascent protein, transport of the 
molecule to cell surface and enhanced stability of the protein (Lambert et al., 2004). TIMP-3 
has also one glycosylation site. 
TIMP-1 mRNA or protein overexpression was found in thyroid papillary cancers compared to 
normal tissue or goiters (Hawthorn et al., 2004; Maeta et al., 2001). Shi et al. (1999) investigated 
TIMP-1 gene expression in 39 primary thyroid tumors to see whether there is a correlation 
between TIMP-1 expression and the aggressiveness of the disease. They also transfected 
human TIMP-1 cDNA into a papillary thyroid carcinoma cell line (NPA) to study the effect of 
TIMP-1 expression on its invasive potential using an in vitro tumor invasion assay. The results 
showed that TIMP-1 mRNA level correlated directly with tumor aggressiveness: the highest 
number of TIMP-1 transcripts was found in stages III and IV versus benign goitres. However, 
overexpression of TIMP-1 by gene transfer resulted in a significant suppression of the 
malignant phenotype of NPA cells which suggests that TIMP-1 may function as a thyroid 
tumor invasion/metastasis suppressor. To explain these discrepancies, the authors suggested 
that the increased levels of TIMP-1 transcripts observed in cancer samples came from stroma 
cells to counteract tumor invasion and metastasis. 
Kebebew et al. (2006) performed a real-time quantitative reverse-transcriptase polymerase 
chain reaction (RT-PCR) assay of several candidate diagnostic markers to distinguish benign 
from malignant thyroid neoplasms, and to predict the extent of the disease. TIMP-1 mRNA 
expression level as well as ECM1 (extracellular matrix protein 1), TMPRSS4 (transmembrane 
protease, serine 4) and ANGPT2 (angiopoietin 2) mRNA levels were found to be 
independent diagnostic markers of malignant thyroid neoplasms. The AUC (the area under 
the receiver operating characteristic (ROC) curve) for  4 diagnostic genes in combination 
was 0.993 with sensitivity of 100%, specificity of 94.6%, positive predictive value of 96.5%, 
and negative predictive value of 100%. Thus the RT-PCR multigene assay involving TIMP1 
is an excellent diagnostic marker for differentiated thyroid cancer and it will be a  helpful 
adjunct to FNA biopsy of thyroid nodules. 
The plasma concentration of MMP-1, 2, 3, 8 and 9 as well TIMP-1 and 2 was evaluated by 
enzyme-linked immunosorbent assay (ELISA) in patients with thyroid cancers (papillary, 
anaplastic and medullary) and in healthy subjects. The author suggests that, predominance 
of MMP-2 over TIMP-2 and TIMP-1 over MMP-1 is a common feature in patients with 
thyroid cancer (Komorowski et al., 2002). 
Recently Nam et al. (2011) have studied the expression of matrix metalloproteinase-13 
(MMP-13) and tissue inhibitor of metalloproteinase-13 (TIMP-3) in thyroid cancer by RT-
PCR. They found that MMP-13 and TIMP-3 expression levels were significantly decreased in 
PTC samples compared with normal thyroid tissues. 
3.7 Dipeptidyl peptidase IV 
Dipeptidyl peptidase IV (DPPIV), assigned to the CD26 cluster, is a multifunctional protein 
expressed on epithelial cells and lymphocytes. DPPIV is a type II transmembrane 
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glycoprotein which consists of a large extracellular domain (C-terminus) connected by a 
flexible stalk region to a hydrophobic transmembrane domain and short intarcellular tail (N-
terminus) (Kotacková et al., 2009). It preferentially cleaves N-terminal dipeptides from 
polypeptides with proline or alanine in the penultimate position and regulates the activities 
of a number of hormones, neuropeptides, cytokines and chemokines (Havre et al., 2008; 
Kotacková et al., 2009). DPPIV palys an important role in immune regulation, signal 
transduction, chemotaxis, cell adhesion and apoptosis. It is suggested that DPPIV is also 
involved in the neoplastic transformation and tumor progression (Pro & Dang, 2004; 
Kotacková et al., 2009).  
Numerous early studies showed that DPPIV is abnormally expressed in thyroid carcinomas 
and may be useful for the diagnosis of thyroid tumors (Aratake et al., 1991; Kotani et al., 
1992; Tanaka et al., 1995; Umeki et al., 1996; Tang et al., 1996; Hirai et al., 1999). DPPIV-like 
enzymatic activity and DPPIV protein expression were up-regulated in thyroid cancers. 
However, DPPIV positivity is limited to the group of well-differentiated carcinomas, 
particularly papillary carcinoma (Kholová et al., 2003; de Micco et al., 2008). DPPIV 
sensitivity to malignant follicular tumors including the  follicular variant of PTC was low 
with a misdiagnosis rate of 20–30%, especially with tumors presenting Hürthle or tall-cell 
features. Although, the use of DPPIV can increase specificity and positive predictive value 
of the cytological diagnosis, the value of the marker in the individual cases is very limited 
(Kholová et al., 2003). The analysis of DPPIV mRNA level in 102 PTCs and 77 normal 
thyroid fragments with the use of Q-PCR reaction confirmed the increase of DPPIV 
expression in papillary thyroid carcinoma. However, the ROC  analysis revealed that the 
diagnostic efficiency of DPPIV estimation is limited. Thus diagnostic usefulness of DPPIV as 
a single PTC marker is also doubtful (Ożóg et al. 2006).  
3.8 E-cadherin and dysadherin 
Cadherins are members of a large family of transmembrane glycoproteins, many of which 
participate in Ca2+-dependent homophilic cell-cell adhesion and play an important role in 
the formation of tissue architecture (Shapiro & Weis, 2009). E-cadherin is necessary for 
normal epithelial function. Dysadherin is a cancer-associated cell membrane glycoprotein. It 
inactivates E-cadherin function in a post-transcriptional manner, has an anti-cell-cell 
adhesion function and plays an important role in tumor progression and metastasis (Ino et 
al., 2002).  
Several authors have investigated the expression of E-cadherin in thyroid cancers 
(Scheumman  et al., 1995; Serini et al., 1996; von Wasielewski et al., 1997; Kapran et al., 2002; 
Rocha et al., 2003; Kato et al., 2002; Choi et al. 2005; Brecelj et al., 2005). In general, it appears 
that E-cadherin expression is retained in follicular neoplasms but  it is reduced in papillary 
carcinomas and lost in  anaplastic and poorly differentiated carcinomas. Reduction or loss of 
E-cadherin has been correlated with widely invasive growth and lymph node metastases 
(Naito et al., 2001). E-cadherin reactivity is reported to be an important prognostic factor in 
papillary thyroid carcinomas (Scheumman et al., 1995; Rocha et al., 2003). Lack of  
E-cadherin expression has been considered as an adverse prognostic factor for survival. 
Dysadherin expression in thyroid cancer was reported by two studies. Sato et al. (2003) 
analyzed by immunohistochemistry dysadherin and E-cadherin expression in 92 thyroid 
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carcinomas. Dysadherin was detected in 39 of 51 papillary carcinomas and in all 31 
undifferentiated carcinomas but not in follicular carcinomas or normal thyroid tissue 
controls. Dysadherin expression correlated significantly with tumor size, regional lymph 
node metastasis, and distant metastasis of the primary carcinoma. A significant association 
was also observed between dysadherin expression and death from thyroid carcinoma. 
Dysadherin expression showed a significant negative  correlation with E-cadherin 
expression (Sato et al., 2003). 
Batistatou et al. (2008) compared the dysadherin expression in papillary carcinomas and 
papillary microcarcinomas (PMC) to find out whether there are any differences in the cell–
cell adhesion system between these two malignancies that have different biological 
behavior. PMC has been defined as a papillary neoplasm measuring 1cm or less in diameter 
and usually remains clinically silent and is often identified incidentally in surgically 
removed thyroid glands for other reasons (e.g. nodular hyperplasia, thyroiditis).  
A statistically significant difference in dysadherin and E-cadherin expression between PC 
and PMC and a negative correlation between E-cadherin and dysadherin expression 
regardless of tumor size were noted (Batistatou et al., 2008). 
3.9 Mucins 
Mucins are defined as high molecular weight glycoproteins that contain tandem repeat 
structures  extensively glycosylated through GalNAc O-linkages at the threonine and serine 
residues. To date, twenty one members of human mucin (MUC) family have been reported 
and they are designed chronologically in order of discovery. On the basis of their structural 
and physiologic characteristics, mucins have been divided into three sub-classes: the 
secreted/gel-forming mucins, the soluble mucins, and the membrane- associated mucins 
(Kufe, 2009; Ohashi et al., 2006).  
Mucins are multifaceted glycoproteins that play a crucial role in maintaining homeostasis 
and promoting cell survival. They form a physical barrier, which separates an apical surface 
of epithelial cells from the external environment and protects against infection and 
proteolytic degradation. The membrane-associated mucins are anchored to the surface of the 
cell by a transmembrane domain and then have short cytoplasmic tail that interacts with 
cytoskeletal elements and cytosolic adaptor proteins. Therefore, they can act as putative 
receptors that engage diverse signaling pathway linked to differentiation, proliferation and 
apoptosis. Several reports indicate that aberrant upregulations of mucins especially 
transmembrane forms may promote the malignant phenotype of human carcinomas. In 
many types of tumor overexpression of transmembrane mucins contribute to the 
oncogenesis by disrupting epithelial polarity and cell-cell interactions, to constitutive 
activation of growth and survival pathways and to blocking stress-induced apoptosis and 
necrosis (Bafna et al., 2010; Kufe, 2009; Carraway et al., 2003).  
The production of mucins has been relatively frequently observed in thyroid carcinomas. In a 
study of 142 cases of thyroid neoplasms, Mlynek et al. (1985) found mucinous substances, 
which occurred in about 50% of the papillary and medullary carcinomas, 35% of the follicular 
carcinomas and 21% of the anaplastic varieties. The most widely studied mucin, associated 
with thyroid malignancies is MUC1, encoded by gene located on the chromosome 1q21-24. 
Wreesmann et al. (2004) suggested that up-regulation of MUC1 expression in papillary thyroid 
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carcinoma correlates with 1q21 amplifications and aggressive behavior. The MUC1 gene 
overexpression was present in 97,5% of tall-cell variant of PTCs (TCV) as compared with only 
35% of conventional PTCs. These results are in contrast to the previous analysis of Bièche et al. 
(1997) who detected no MUC1 gene amplification in 14 tumor samples (6 adenomas and 8 
PTC) informative for the MUC1 gene. However, these studies showed higher MUC1 
expression level in 6 out of 11 papillary carcinoma cases in comparison with 10  
macrofollicular adenoma cases and normal thyroid tissue. Moreover, the authors observed 
that intracytoplasmic MUC1 staining occurred in 75% (3/4) of “high-risk” papillary thyroid 
carcinomas and in only 28,5% (2/7) of the “low-risk” PTC without extrathyroidal invasion or 
lymph node involvement, suggesting that MUC1 can be associated with more aggressive 
tumors. Indeed, comparing human thyroid cancer cell lines, Patel et al. (2005) found increased 
MUC1 expression in aggressive thyroid cancer cell lines (8305C, KAT4, ARO, BHP2-7, BHP10-
3, BHP7-13, BHP18-21) but not in other papillary and follicular thyroid cancer cell lines (KAT5, 
KAT10, NPA, WRO, FRO). In addition, they demonstrated that targeting MUC1 with 
monoclonal antibody selectively affects cell viability and confirmed that MUC1 plays a crucial 
role in the thyroid behavior. Furthermore, a relationship was observed between cytoplasmic 
MUC1 and cyclin D1 immunostaining in the conventional PTCs and in papillary 
microcarcinomas (PMCs), implying that MUC1 may be involved in the regulation of Wnt 
pathway and has a role in B-catenin/cyclin D1 signaling. However, due to a very broad MUC1 
expression in different histological variants, the authors were not able to determinate its 
prognostic utility (Abrosimov et al., 2007). Magro et al. (2003) found that MUC1 may co-exist 
in variety of glycosylated forms in different cellular compartments. They supposed that post-
translational modification of mucins, rather than alterations in expression levels, may be 
stronger associated with tumor progression and specific glycosylation traits of MUC1 and 
could be an ancillary tool in histopathological diagnosis. Other investigators found MUC1 
mRNA overexpression in 15 cases of PTC in contrast to 22-follicular adenomas and 22-normal 
thyroid tissues (Baek et al., 2007). More recently, Morari et al. (2010) basing on the study of 410 
patients reported that MUC1 expression distinguished benign from malignant thyroid tissue 
with sensitivity of 89%; specificity of 52%; predictive positive value=75%; predictive negative 
value=74%. In conclusion, they suggested that MUC1 is not a reliable prognostic marker but 
may be useful in characterization of thyroid carcinomas, especially the follicular patterned 
thyroid lesions. The expression of other mucins in thyroid neoplasms has been poorly 
investigated. Nam et al. (2011) have suggested that MUC4 and MUC15 are the other important 
mucins associated with thyroid transformation. They showed significantly increased MUC4 
and MUC15 mRNA level and positive immunoreactivities in PTC compared with normal 
tissue. High MUC4 expression correlated with small tumor size and papillary thyroid 
microcarcinoma subtype whereas overexpression of MUC15 was associated with age, the 
presence of multifocality and distant metastasis. The results of this study suggest, that MUC4 
and MUC15 may play a crucial role in thyroid malignancy, especially the MUC15 may be a 
new prognostic marker and potential therapeutic target. However, there are some 
discrepancies  between the previously published reports that indicated weakly positive or 
negative MUC4 staining of both benign and malignant thyroid carcinomas (Baek et al., 2007; 
Magro et al., 2003). The expression of MUC2, MUC3, MUC5AC, MUC5B and MUC6 in thyroid 
neoplasms has been tested, though none of these glycoproteins was associated with 
clinicopathological features of thyroid carcinomas (Magro et al., 2003; Alves et al., 1999). The 
clinical and prognostic significance of mucins in thyroid tumors is still an open question.  
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4. Galectins 
Galectins are endogenous lectins defined by shared consensus amino acid sequences and an 
affinity for -galactose containing oligosaccharides. Fifteen members of galectin family have 
been identified and classified into three subgroups based on their structure: prototype 
(galectin-1, 2, 5, 10, 11, 13, 14, 15 ), tandem repeat type (galectin-6, 8, 9, 12) and chimera type 
(galectin-3). The presence of at least one carbohydrate recognition domain (CRD) is a 
common characteristic of galectins (Krześlak & Lipińska, 2004; Elola et al., 2007; Boscher et 
al., 2011). Galectins have both intra- and extracellular localization. Galectins can be secreted 
by non-classical pathway and depending on the cell type or differentiation state, they are 
found in the cytoplasm and the nucleus, on the cell surface and in the extracellular matrix 
(Hughes, 2001; Haudek et al., 2010; Garner & Baum, 2008). Galectins have been shown to 
play roles in diverse biological processes, such as embryogenesis, adhesion and proliferation 
of cells, apoptosis, mRNA splicing and modulation of immune response (Krześlak & 
Lipińska, 2004; Elola et al., 2007; Boscher et al., 2011).  
Among various galectins, galectin-1, 3 and 7 have gained attention as potential markers of 
thyroid malignancy. However, the data concerning galectin -1 and 7 expression in thyroid 
are very limited. Chiariotti et al. (1995) analyzed mRNA and protein levels of galectin-1 in 
74 human thyroid specimens of neoplastic, hyperproliferative and normal tissues. Galectin-1 
mRNA levels was increased in 28 of 40 papillary carcinomas and in 6 of 7 anaplastic 
carcinomas compared with normal or hyperplastic thyroid. Immunohistochemical analysis 
of normal thyroid and papillary carcinoma sections revealed a higher content of galectin-1 
protein in neoplastic cells than in normal cells. Similarly Xu et al. (1995) showed that all 
studied by them thyroid malignancies of epithelial origin (i.e., papillary and follicular 
carcinomas) and metastatic lymph node from a papillary carcinoma expressed high levels of 
galectin-1. In contrast neither benign thyroid adenomas nor adjacent normal thyroid tissue 
expressed galectin-1. There are only two studies concerning galectin-7 expression in thyroid 
cancers (Rorive et al., 2002; Than et al., 2008). The profile of galectin-7 expression is different 
from that of galectin-1 and 3. The results of  immunohistochemical analysis revealed that 
this galectin is markedly down-regulated in adenomas compared with multinodular goiters 
and carcinomas (Rorive et al., 2002). Than et al. (2008) did not show any diagnostic value of 
galectin-7 in thyroid malignancy, even for a simple differentiation between obvious benign 
and malignant thyroid lesions . 
In contrast to galectin-1 and 7, galectin-3 is one of the best studied molecular markers for 
thyroid diagnosis (for rewiew see Sanabria et al., 2007; Chiu et al., 2010) . The expression 
of this protein was widely studied both in cancer tissues and in cytological specimens. 
Numerous studies have reported that galectin-3 is a very sensitive and reliable diagnostic 
marker for identification of thyroid carcinomas with high sensitivity and specificity 
(Orlandi et al., 1998; Gasbarri et al., 1999; Inohara et al., 1999; Bartolazzi et al., 2001; 
Saggiorato et al., 2001,2004; Pisani et al., 2004). However there are studies which did not 
confirm this diagnostic utility of galectin-3 (Niedziela et al., 2002, Mehrotra et al.,  2004, 
Mills et al., 2005)  The discrepancies observed in these reports could have resulted from 
different methods used for galectin-3 expression analysis. These methods differ in sample 
preparation details, the used antibody, dilution of antibodies, assessement of positive 
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results (percentage of marked cells and intensity of staining). Moreover, in the thyroid 
gland, oxyphilic cells are rich in endogenous biotin and galectin-3 immunocytochemistry 
may provide false-positive results in oxyphilic cell lesions due to biotin-based detection 
systems (Volante et al.,  2004).  
Recently, the diagnostic utility of galectin-3 in distinguishing benign from malignant 
follicular thyroid nodules was evaluated in a multicenter trial  comprised a large cohort of 
patients (Bartolazzi et al., 2008). Galectin-3 expression analysis was applied preoperatively 
on 465 follicular thyroid FNAB samples and  diagnostic accuracy was compared with final 
histology. Galectin-3 expression had an overall reported sensitivity of 78%, specificity of 
93% and accuracy of 88% for distinguishing benign and malignant thyroid tumors. Similar 
results were obtained in two center trial reported by Franco et al. (2009). They compared 
galectin-3 staining results in suspicious or indeterminate FNABs samples with the histologic 
diagnosis of the thyroidectomy specimens. Galectin-3 expression was found to have 
sensitivity of 83%, specificity of 81%, positive predictive value of 84%, and negative 
predictive value of 80%.  
Few studies have evaluated the correlation between galectin-3 expression and 
clinicopathological parameters of thyroid cancers such as tumor size and grade, capsular 
invasion or lymph node metastasis status. The galectin-3 expression level in follicular 
carcinoma was significantly increased with the degree of vascular or capsular invasion (Ito 
Y et al. 2005). High galectin-3 expression was also associated with lymph node metastasis in 
MTC (Faggiano et al., 2002; Cvejic et al., 2005). Contrary, Kawachi et al. (2000) reported 
significantly higher galectin-3 expression in the primary foci of the thyroid tumors with 
lymph node metastases, but they found lower levels of galectin-3 in their metasatsis 
offspring. Recently, Türköz et al. (2008) suggested that galectin-3 overexpression is more 
profound in early stages of papillary carcinoma, and its expression intensity decreases 
during tumor progression. 
Two studies have analyzed the serum level of galecin-3 in thyroid cancer patients (Inohara 
et al. 2008; Saussez et al., 2008). They measured serum level of galectin-3 by ELISA method 
and compared with histological diagnosis after thyroidectomy. Although Sauessez et al. 
(2008) showed that higher serum level of galectin 3 was associated with thyroid disease 
there were no significant differences between benign and malignant thyroid tissues. Inohara 
et al. (2008) showed that serum galectin concentration in patients with papillary carcinomas 
did not differ significantly from that in patients with follicular carcinoma or adenoma and in 
healthy individuals.  
Studies of Bartolazzi et al. (2008) and Franco et al. (2009)  suggest that galectin-3 expression 
analysis may represent useful diagnostic method for those follicular nodules that remain 
indeterminate by cytological diagnosis and may improve the selection of patients for 
surgery. However before it can be used in clinical practice there is an urgent need for 
validation of methods of galectin-3 expression analysis. Some other studies suggest that 
diagnostic usefulness of galectin-3 may be significantly increased by combining with other 
potential thyroid cancer markers such as HBME1, cytokeratin-19, DPPIV, CD44v6, thyroid 
peroxidase (Aratake et al., 2002; Weber et al., 2004; Maruta et al. 2004; de Matos et al., 2005; 
Prasad et al., 2005; Papotti et al., 2005; Liu et al., 2008; Barut et al., 2010).  
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5. Conclusion 
Fine needle aspiration biopsy (FNAB) is a practical and the most effective diagnostic 
technique for the preoperative detection of malignant nodule. However, the important 
limitation of FNAB is the lack of sensitivity in the evaluation of follicular neoplasms due to 
its inability to differentiate benign follicular lesions from their malignant counterparts. 
Moreover, for definite diagnosis of malignancy a complete excision with unequivocal 
evidence of capsular or vascular invasion is required. Therefore, new markers that may 
allow for accurate diagnosis of thyroid malignancy and eliminate potentially unnecessary 
surgery are needed. Glycosylation changes and the analyses of expression of some 
glycoproteins or galectins can provide a novel strategy for improvement of thyroid cancer 
diagnostics. So far, the most promising results have been obtained in the case of galectin-3 
expression. Currently an improved galectin-3 immunodetection method represents a new 
methodological approach that can be used to optimize the preoperative selection of thyroid 
nodules. Further studies concerning alterations of glycosylation and glycoprotein patterns in 
thyroid pathological specimens may potentially  lead to the discovery of novel biomarkers. 
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